The company has invested heavily in R&D and generated a portfolio of patents covering unique marine gene products for the molecular biology sector, and products with potentials within the pharmaceutical sector, such as beta-1,3/1,6-glucan formulations. The company has a strong foundation in basic research in both this and the recombinant technology sectors.
Basic research on the mode of action of the various proprietary beta-1,3/1,6-glucan products at a cellular/molecular level has been the foundation for scientific experiments with whole animals and a comprehensive series of commercial trials with various farm animals. Experience over a period of more than 20 years has confirmed that beta-1,3/1,6-glucan enhances overall disease resistance and improves health. Studies have shown that pure beta-1,3/1,6-glucan is a non-toxic modulator of various immune functions in the body, and affects many immunity related disorders.
Biotec Pharmacon has initiated a clinical development programme with drug candidates that enhance immunity and counteract the negative effects of immune related disorders. Product formulations that are effective when administered onto mucous surfaces, either alone or in combination with other medications or vaccines, have been given priority.
Beta-1,3/1,6-glucan interacts with cells that control innate immune mechanisms and orchestrates other immune reactions, especially the macrophages. The product therefore has many applications within human medicine, including general infection prophylaxis, immune therapy of cancer, and to counteract various sufferings that are related to imbalanced immune responses.
R&D-programs are also outsourced at cooperating academic and scientific institutions in Norway and abroad, in particular in the USA.
The intellectual property value of Biotec Pharmacon is being secured and developed through patents and trademarks, through control of the manufacturing technology and by a highly educated staff with a varied background and broad international experience.[/td_text_with_title]
As Warren Buffet points out the hard part in stock picking is not predicting what is going to happen, but when. It can take much longer time than you initially expected for a value case to unfold. The above is true for great companies in the value sphere. Today I am looking at 3 not-so-great...
The 7th July Biotec Pharmacon and Smith & Nephew decided to end the discussion about a Woulgan®distribution agreement. Consequently, Biotec will therefore accelerate the on-going process to pursue an alternative market channel strategy, which would include distribution agreements with strong regional business partners and distributors. – Following a period of thorough and constructive discussion with Smith & […]